• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

This Cosmetic Surgery Play Looks Attractive for 2020

A solid fourth-quarter report could bring momentum players back to this Israeli company with great growth potential.
By JAMES "REV SHARK" DEPORRE
Jan 09, 2020 | 12:30 PM EST
Stocks quotes in this article: INMD

I have been highlighting some of my top ideas for the year ahead.

So far I've discussed a small biotechnology name with a good chance of being taken over, a technology company on the leading edge of new developments in the cloud and a growing genomics play that could be a sleeper in 2020.

Another name that has good potential in 2020 is InMode (INMD) .

InMode was my "Stock of the Week" in October 2019 when it was trading around $26. It more than doubled and hit $58.76 on Nov. 18. Since then it has been correcting and now seems to have found support around $35 where there is a gap on the chart. I'm looking for a strong earnings report to trigger renewed momentum.

InMode is an Israeli company that develops, manufactures, and sells devices that use its unique, minimally-invasive radio-frequency (RF) technology in cosmetic surgery, dermatology, gynecology, and various other medical specialties. The company sells an RF energy source platform with interchangeable handpieces which generates 91% of its revenue.

Eighty percent of the company's sales are in the U.S., but it is expanding quickly into other countries, including Spain, India, and Australia. The company is launching three new RF platforms for dealing with cellulite, skin tightening, and face and neck tightening.

The company's IPO at $14 per share was on Aug. 8. It released second-quarter results a few days later, which pushed the stock into an uptrend. Revenues were up 55%, and earnings per share more than doubled to $0.45 from $0.21. Results for the third quarter were equally strong with revenues up 57% and EPS of $0.46.

Earnings are expected to hit $1.49 per share for full-year 2019 and grow to $1.65 in 2020, but the likelihood of additional upside is good. The stock trades at a trailing P/E multiple of 31x and is not cheap, but the strong growth will likely command a premium multiple.

This company has great growth potential, not only from the broadening of its product line, but by expansion into international markets. It should post a solid fourth-quarter report, which may bring back the momentum players that drove it to the highs back in November.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long AUPH, DDOG, PSNL and INMD.

TAGS: IPOs | Investing | Small Cap | Stocks

More from Stocks

Market Looks Good from Above, Poor From Below

James "Rev Shark" DePorre
Jun 29, 2022 4:21 PM EDT

The major indexes held up well, but underneath, it wasn't pretty.

This FAANG Stock's Technicals Are at a Summer Crossroads

Bob Lang
Jun 29, 2022 3:30 PM EDT

Summer is a time when this name usually gains momentum. Will it this time?

Kass: Untapped Homeowners Equity and Imbedded Gains Will Be a Ballast to Growth

Doug Kass
Jun 29, 2022 3:00 PM EDT

Homeowners equity has more than tripled in the last decade.

Good High Yield Stocks Don't Have to Be Pricey. We've Got 3 to Prove It

Bob Ciura
Jun 29, 2022 1:32 PM EDT

Here are three cheap dividend stocks that should pay off big.

Don't Expect Fed Relief Anytime Soon

Maleeha Bengali
Jun 29, 2022 12:38 PM EDT

Major selloffs in recent years were accompanied by Fed cuts and market bottoms, but this time is different.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:51 PM EDT PAUL PRICE

    We should be in for better starting soon.

    Window dressing tomorrow, the last day of ...
  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login